toxicity – Medxy AI

Optimizing Neck Radiation in Advanced Differentiated Thyroid Carcinoma: Balancing Locoregional Control and Toxicity through Field Reduction

By MedXY 10/26/2026

This study demonstrates that reducing radiation fields in advanced differentiated thyroid carcinoma lowers toxicity without compromising locoregional tumor control, supporting personalized radiotherapy strategies.

Clinical Updates Oncology Radiology Specialties

Sequential Chemoradiotherapy vs Induction Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Efficacy and Safety Insights from a Phase 3 Randomized Trial

By MedXY 08/23/2025

A multicenter phase 3 trial demonstrates that sequential chemoradiotherapy is noninferior to induction plus concurrent chemoradiotherapy for stage III/IVA nasopharyngeal carcinoma with fewer acute toxicities.

$Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial$

Clinical Updates news Oncology Radiology Specialties Urology

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY 08/03/2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.

Clinical Updates news Oncology Specialties

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies

By MedXY 07/30/2025

Antibody-drug conjugates (ADCs) have transformed breast cancer therapy but bring notable toxicity risks. This review examines the clinical evidence, adverse event management, and future directions for optimizing ADC use.